![FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN](https://media.cnn.com/api/v1/images/stellar/prod/230109124641-moderna-bivalent-vaccine.jpg?c=16x9&q=h_720,w_1280,c_fill)
FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN
![COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - CROI Conference COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - CROI Conference](https://www.croiconference.org/wp-content/uploads/sites/2/posters/2023/Figures/1430597.png)
COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - CROI Conference
![Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm715152e1_BivalentVaccineEffectiveness_IMAGE_16Dec2022_1200x675.jpg?_=42783)
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
![Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ](https://www.bmj.com/content/bmj/382/bmj-2022-075286/F3.large.jpg)
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
![Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada | medRxiv Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2023/04/11/2023.04.11.23288403/F1.large.jpg)
Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada | medRxiv
![Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population | Nature Medicine Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-023-02219-5/MediaObjects/41591_2023_2219_Fig1_HTML.png)
Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population | Nature Medicine
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)